Surgical Management of the Primary Tumor in Stage IV Small Intestinal Neuroendocrine Tumors: To Operate or Not to Operate, That Is the Question

[1] Dasari A(2017)Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States JAMA Oncol. 3 1335-1342

[2] Shen C(2021)Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States JAMA Netw Open. 4 e2124750-163

[3] Halperin D(2019)Incidence of neuroendocrine tumors in the United States from 2001-2015: a United States cancer statistics analysis of 50 states Cureus. 11 e4322-898

[4] Zhao B(2021)Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences? Curr Oncol Rep 23 43-2491

[5] Zhou S(2014)Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature Endocr Relat Cancer. 21 153-21

[6] Xu Y(2006)Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival Surgery. 140 891-e458

[7] Xu Z(2022)Overall and stage-specific survival of patients with screen-detected colorectal cancer in European countries: a population-based study in 9 countries Lancet Reg Heal Eur. 21 100458-7832

[8] Wang L(2021)Update on incidence, prevalence, treatment and survival of patients with small bowel neuroendocrine neoplasms in the Netherlands World J Surg. 45 2482-534

[9] Dai S(2014)Review Recommendations for management of patients with neuroendocrine liver metastases Lancet Oncol 15 e8-273

[10] Chen M(2022)Upfront small bowel resection for small bowel neuroendocrine tumors with synchronous metastases: a propensity-score matched comparative population-based analysis Ann Surg. 276 e450-147

[1] Dasari A(2017)Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States JAMA Oncol. 3 1335-1342

[2] Shen C(2021)Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States JAMA Netw Open. 4 e2124750-163

[3] Halperin D(2019)Incidence of neuroendocrine tumors in the United States from 2001-2015: a United States cancer statistics analysis of 50 states Cureus. 11 e4322-898

[4] Zhao B(2021)Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences? Curr Oncol Rep 23 43-2491

[5] Zhou S(2014)Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature Endocr Relat Cancer. 21 153-21

[6] Xu Y(2006)Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival Surgery. 140 891-e458

[7] Xu Z(2022)Overall and stage-specific survival of patients with screen-detected colorectal cancer in European countries: a population-based study in 9 countries Lancet Reg Heal Eur. 21 100458-7832

[8] Wang L(2021)Update on incidence, prevalence, treatment and survival of patients with small bowel neuroendocrine neoplasms in the Netherlands World J Surg. 45 2482-534

[9] Dai S(2014)Review Recommendations for management of patients with neuroendocrine liver metastases Lancet Oncol 15 e8-273

[10] Chen M(2022)Upfront small bowel resection for small bowel neuroendocrine tumors with synchronous metastases: a propensity-score matched comparative population-based analysis Ann Surg. 276 e450-147